Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
A triple monoamine reuptake inhibitor (serotonin, norepinephrine, dopamine) originally developed for Parkinson's and Alzheimer's that showed remarkable weight loss in Phase 2 trials. Now being developed specifically for obesity.
A GLP-1 receptor agonist originally developed for type 2 diabetes, now widely prescribed for weight management. One of the most commercially successful peptide drugs in history.
Inhibits reuptake of serotonin, norepinephrine, and dopamine, reducing appetite and increasing energy expenditure through central nervous system modulation. Different mechanism than GLP-1 agonists.
Mimics the incretin hormone GLP-1, stimulating insulin secretion, suppressing glucagon release, slowing gastric emptying, and reducing appetite through central nervous system signaling. The result is improved blood sugar control and significant weight loss.
- Weight management (investigational)
- Appetite suppression
- Metabolic rate enhancement
- Weight management
- Type 2 diabetes treatment
- Blood sugar regulation
- Cardiovascular risk reduction
- Increased heart rate
- Dry mouth
- Insomnia
- Constipation
- Potential cardiovascular concerns
- Not yet approved — full safety profile unknown
- Nausea and vomiting (common, usually transient)
- Pancreatitis (rare but serious)
- Gallbladder issues
- Potential thyroid tumor risk (animal studies)
- Muscle mass loss alongside fat loss
- GI side effects (diarrhea, constipation)
Phase 3 clinical trials ongoing. Phase 2 showed up to 12.8% body weight loss at 24 weeks. Approved in Mexico (2024). Not FDA-approved in the US.
FDA-approved as Ozempic (diabetes, 2017), Wegovy (weight management, 2021), and Rybelsus (oral, diabetes, 2019). Multiple dosage forms and indications approved.
- Tesofensine for treatment of obesity
2008 · PubMed
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.